AdipoGen Life Sciences

SARS-CoV-2 Neutralizing Antibodies Detection Kit (B.1.617.2 Variant, Delta)

CHF 840.00
In stock
AG-48B-0007-KI0196 wellsCHF 840.00
More Information
Product Details
Synonyms COVID-19 Neutralizing Antibodies Detection Kit (B..1.617.2 Variant, Delta); 2019-nCoV Neutralizing Antibodies Detection Kit (B..1.617.2 Variant, Delta); 2019-nCoV Spike Protein S1 (RBD) Neutralizing Antibodies Detection Kit (B..1.617.2 Variant, Delta)
Product Type Kit
Application Set Qualitative ELISA

To measure the presence of neutralizing/blocking antibodies in human serum/plasma that inhibit the binding of the SARS-CoV-2 Spike (RBD) (B.1.617.2 Variant, Delta) protein to its human receptor ACE2.

Crossreactivity Avian
Guinea pig

Contains sufficient materials for 96 reactions

Sample Type Plasma
Detection Type Colorimetric
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Plate and reagents should reach room temperature before use.
Use/Stability 12 months after the day of manufacturing. See expiry date on ELISA Kit box.
Manual Download PDF
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many wild animals. Recently, a new severe acute respiratory syndrome β-coronavirus called SARS-CoV-2 has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells.The SARS-CoV-2 Neutralizing Antibodies Detection Kit (B.1.617.2 Variant, Delta) contains key reagents required to test the presence of functional neutralizing antibodies against SARS-CoV-2 (variant B.1.617.2) present in the serum or plasma or/and to test the cross-reaction of SARS-CoV-2 neutralizing antibodies directed to previous variants. It is an easy and fast alternative to the classical neutralization assay using Vero E6 cells. This Detection Kit is based on a colorimetric reaction, which measures the binding of the RBD of the Spike S protein from SARS-CoV-2 (variant Kappa) to its human receptor ACE2. The presence of neutralizing/blocking antibodies in the samples are detected by reduction of signal indicating the inhibition of the Spike-ACE2 binding. 

Recently, a new variant of SARS-CoV-2, called B.1.617 was detected in India. Three sublineages have been found, B.1.617.1 (variant Kappa) and B.1.617.3 containing 4 mutations in the Spike protein with a double mutations in the Receptor Binding Region (L452R, E484Q) and B.1.617.2 (variant Delta) that is different since it contains the mutation T478K instead of E484Q. The variant Delta (B.1.617.2) of the SARS-CoV-2 coronavirus has evolved as fast-growing variant outpacing other variants.

Product References
  1. Efficacy and impact of SARS‑CoV‑2 vaccination on cancer treatment for breast cancer patients: a multi‑center prospective observational study: M. Terada, et al.; Breast Cancer Res. Treat. 195, 311 (2022)
  2. Pilot Study for Immunogenicity of SARS-CoV-2 Vaccine with Seasonal Influenza and Pertussis Vaccines in Pregnant Women: C.-J. Shen, et al.; Vaccines 11, 119 (2023)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.